1. Introduction {#sec1-molecules-22-00053}
===============

The heterocycle benzoxazepines are privileged scaffolds in natural biologically products \[[@B1-molecules-22-00053],[@B2-molecules-22-00053],[@B3-molecules-22-00053],[@B4-molecules-22-00053]\], pharmaceutical chemistry \[[@B5-molecules-22-00053],[@B6-molecules-22-00053]\] and functionalized materials \[[@B7-molecules-22-00053],[@B8-molecules-22-00053],[@B9-molecules-22-00053],[@B10-molecules-22-00053]\]. As such, Sintamilv (**I**) is an efficient antidepressant \[[@B11-molecules-22-00053]\]; H1 receptor antagonist (**II**) is a selective antihistaminic agent \[[@B12-molecules-22-00053]\]; and Sintamil (**III**) is a benzoxazepine analogue ([Scheme 1](#molecules-22-00053-sch001){ref-type="scheme"}) \[[@B13-molecules-22-00053]\]. Furthermore, the therapeutic applications of benzoxazepines are for the central nervous system, along with anti-breast cancer activity and inhibitors of HIV \[[@B14-molecules-22-00053],[@B15-molecules-22-00053]\].

Currently, the challenge in organic synthesis is developing an efficient and eco-friendly protocol, especially in the area of drug discovery and natural products. Benzoxazepines are generally synthesized by condensation of 2-aryloxyethylamines with 2-formylbenzoic acid \[[@B16-molecules-22-00053]\]. Others have also been synthesized from amides \[[@B17-molecules-22-00053]\] and amino acids \[[@B18-molecules-22-00053],[@B19-molecules-22-00053]\]. However, most of these methodologies are associated with several drawbacks, such as low synthetic efficiency and sensitivity. Thus, a remarkable gap remains in the search of economical synthesis methods. Tandem transformation is one of the most effective ways to achieve this goal. Considering the above points, herein we report the tandem reaction green protocol for the synthesis of benzo-1,4-oxazepine pharmaceutical derivatives.

The reaction conditions were screened based on a model reaction of phenylamine **1a** and (1-chloro-vinyl)-benzene **2a** ([Table 1](#molecules-22-00053-t001){ref-type="table"}). The ligands were mainly based on the derivatives of 2-(2-dimethylamino-vinyl)-1*H*-inden-1-ol. It was discovered that ligand **L1** was the ideal choice for this transformation (Entries 5--10). CuI exhibited superior catalytic efficiency over all other examined Cu^I^ catalysts (Entries 1--5), and Cs~2~CO~3~ turned out to be the proper base additive (Entries 11--12). Meanwhile, the reaction temperature was 100 °C (Entries 15--16).

With the optimal conditions established, the reaction scope was further investigated. A wide array of phenylamine **1** and ally halide **2** was subjected to this reaction in moderate to good yields ([Table 2](#molecules-22-00053-t002){ref-type="table"}). Phenylamine derivatives bearing either an electron-withdrawing or electron-donating group reacted smoothly with **2**. This transformation is applicable for *para*-substituted phenylamines. Chloroethylene bearing an electron-donating group showed better reactivity than those with an electron-withdrawing group (All the product spectrums, please see [Supplementary Materials](#app1-molecules-22-00053){ref-type="app"}).

Interestingly, we found that 1-bromo-cyclohexene **4** has also been rapidly synthesized in good yields, and the results are summarized in [Table 3](#molecules-22-00053-t003){ref-type="table"}. In addition, the reaction works well for both bearing electron-donating and electron-withdrawing groups.

On the basis of the above experimental results, we tentatively proposed a reaction mechanism as shown in [Scheme 2](#molecules-22-00053-sch002){ref-type="scheme"}. At the beginning, Cu^I^ activate **6** was been formed through copper iodide coordinating with ligand. Next, complex **6** reacted with vinyl halides by oxidative addition produced a Cu^III^ complex **7**. The complex **7** reacted with aniline obtained the key intermediate complex **8** \[[@B20-molecules-22-00053],[@B21-molecules-22-00053]\]. Selective *ortho*-carbonylation of the phenylamine was determined by Complex **9**. Through the reductive elimination of Complex **9**, Complex **10** was obtained, which regenerates Complex **6** for the next catalytic cycle \[[@B22-molecules-22-00053],[@B23-molecules-22-00053]\]. However, how the ligand promotes this transformation is a part of ongoing study.

2. Results and Discussion {#sec2-molecules-22-00053}
=========================

*2-Phenyl-2,3-dihydro-1H-benzo\[e\]\[1,4\]oxazepin-5-one* (**3a**): A mixture of phenylamine **1a** (0.5 mmol, 46.5 mg), (1-chloro-vinyl)-benzene **2a** (0.6 mmol, 83.4 mg), CuI (10 mol %, 9.5 mg), **L1** (10 mol %, 20.1 mg) and Cs~2~CO~3~ (2 equiv., 325.8 mg) in DMSO (4 mL) was stirred in CO~2~ at 100 °C for 10 h. After completion of the reaction, the mixture was quenched with saturated salt water (10 mL); the solution was extracted with ethyl acetate (3 × 10 mL). The organic layers were combined and dried over sodium sulfate. The pure product was obtained by flash column chromatography on silica gel to afford **3a** 96.8 mg in 81% yield. The spectroscopic data of all of the products are presented below. Yellowish oil. ^1^H-NMR (400 MHz, CDCl~3~): 7.63 (m, 1H), 7.43 (br, 1H), 7.08--7.43 (m, 8H), 5.07 (dd, *J* = 8.0, 5.7 Hz, 1H), 4.08 (dd, *J* = 12.3, 8.0 Hz, 1H), 3.96 (dd, *J* = 12.3, 5.6 Hz, 1H); ^13^C-NMR (100 MHz, CDCl~3~): 168.3, 147.7, 139.1, 132.9, 130.3, 128.6, 127.5, 126.6, 117.8, 116.4, 109.1, 77.6, 60.2; EIMS (*m*/*z*): 239 \[M^+^\]; Anal. Calcd. for C~15~H~13~NO~2~: C, 75.30; H, 5.48; N, 5.85; Found: C, 75.62; H, 5.13; N, 5.68.

*2-p-Tolyl-2,3-dihydro-1H-benzo\[e\]\[1,4\] xazepine-5-one* (**3b**): Yellowish oil. ^1^H-NMR (400 MHz, CDCl~3~): 7.61 (m, 1H), 7.44 (br, 1H), 7.04--7.31 (m, 7H), 5.07 (dd, *J* = 8.0, 5.7 Hz, 1H), 4.07 (dd, *J* = 12.3, 8.0 Hz, 1H), 3.95 (dd, *J* = 12.3, 5.7 Hz, 1H), 2.39 (s, 3H); ^13^C-NMR (100 MHz, CDCl~3~): 168.6, 147.8, 138.3, 135.3, 132.3, 130.5, 128.1, 127.6, 118.2, 115.9, 109.5, 77.5, 60.3, 25.2; EIMS (*m*/*z*): 253 \[M^+^\]; Anal. Calcd. for C~16~H~15~NO~2~: C, 75.87; H, 5.97; N, 5.53; Found: C, 75.50; H, 6.20; N, 5.88.

*2-(4-Chloro-phenyl)-2,3-dihydro-1H-benzo\[e\]\[1,4\] xazepine-5-one* (**3c**): Yellowish oil. ^1^H-NMR (400 MHz, CDCl~3~): 7.64 (m, 1H), 7.47 (br, 1H), 7.07--7.48 (m, 7H), 5.08 (dd, *J* = 8.1, 5.6 Hz, 1H), 4.09 (dd, *J* = 12.3, 8.1 Hz, 1H), 3.95 (dd, *J* = 12.3, 5.6 Hz, 1H); ^13^C-NMR (100 MHz, CDCl~3~): 168.3, 147.7, 139.3, 133.3, 132.4, 130.5, 128.6, 127.8, 118.4, 116.3, 110.1, 77.3, 60.9;EIMS (*m*/*z*): 273 \[M^+^\]; Anal. Calcd. for C~15~H~12~ClNO~2~: C, 65.82; H, 4.42; N, 5.12; Found: C, 65.51; H, 4.61; N, 5.33.

*2-Methyl-2,3-dihydro-1H-benzo\[e\]\[1,4\]oxazepin-5-one* (**3d**): Yellowish oil. ^1^H-NMR (400 MHz, CDCl~3~): 7.62 (m, 1H), 7.42 (br, 1H), 7.05--7.21 (m, 3H), 4.58 (dd, *J* = 12.3, 8.0 Hz, 1H), 3.96 (dd, *J* = 12.2, 5.6 Hz, 1H), 3.12--3.71 (m, 1H), 1.35 (d, *J* = 7.1 Hz, 3H); ^13^C-NMR (100 MHz, CDCl~3~): 168.2, 147.3, 132.8, 130.4, 118.7, 116.6, 109.7, 77.1, 53.1, 18.2; EIMS (*m*/*z*): 177.08 \[M^+^\]; Anal. Calcd. for C~10~H~11~NO~2~: C, 67.78; H, 6.26; N, 7.90; Found: C, 68.14; H, 6.55; N, 7.53.

*7-Chloro-2-phenyl-2,3-dihydro-1H-benzo\[e\]\[1,4\]oxazepin-5-one* (**3e**): Yellowish oil. ^1^H-NMR (400 MHz, CDCl~3~): 7.63 (m, 1H), 7.43 (br, 1H), 7.10--7.46 (m, 7H), 5.08 (dd, *J* = 8.1, 5.6 Hz, 1H), 4.10 (dd, *J* = 12.4, 8.1 Hz, 1H), 3.97 (dd, *J* = 12.4, 5.6 Hz, 1H); ^13^C-NMR (100 MHz, CDCl~3~): 168.3, 147.4, 139.5, 133.2, 130.2, 128.7, 127.5, 126.8, 123.8, 115.4, 109.2, 77.5, 60.2; EIMS (*m*/*z*): 273 \[M^+^\]; Anal. Calcd. for C~15~H~12~ClNO~2~: C, 65.82; H, 4.42; N, 5.12; Found: C, 65.70; H, 4.61; N, 5.44.

*7-Chloro-2-p-tolyl-2,3-dihydro-1H-benzo\[e\]\[1,4\]oxazepin-5-one* (**3f**): Yellowish oil. ^1^H-NMR (400 MHz, CDCl~3~): 7.64 (m, 1H), 7.43 (br, 1H), 7.07--7.38 (m, 6H), 5.08 (dd, *J* = 8.1, 5.9 Hz, 1H), 4.10 (dd, *J* = 12.4, 8.1 Hz, 1H), 3.96 (dd, *J* = 12.4, 5.9 Hz, 1H), 2.40 (s, 3H); ^13^C-NMR (100 MHz, CDCl~3~): 168.2, 147.1, 139.2, 135.8, 133.4, 130.5, 128.7, 126.9, 123.5, 115.5, 109.3, 77.2, 60.4, 25.7; EIMS (*m*/*z*): 287.07 \[M^+^\]; Anal. Calcd. for C~16~H~14~ClNO~2~: C, 66.79; H, 4.90; N, 4.87; Found: C, 66.95; H, 4.63; N, 5.23.

*7-Chloro-2-(4-chloro-phenyl)-2,3-dihydro-1H-benzo\[e\]\[1,4\]oxazepin-5-one* (**3g**): Yellowish oil. ^1^H-NMR (400 MHz, CDCl~3~): 7.66 (m, 1H), 7.46 (br, 1H), 7.09--7.50 (m, 6H), 5.10 (dd, *J* = 8.2, 5.6 Hz, 1H), 4.11 (dd, *J* = 12.4, 8.2 Hz, 1H), 3.96 (dd, *J* = 12.4, 5.6 Hz, 1H); ^13^C-NMR (100 MHz, CDCl~3~): 168.2, 147.4, 139.6, 133.2, 131.8, 130.2, 128.9, 126.7, 123.8, 115.2, 109.6, 77.5, 60.3; EIMS (*m*/*z*): 307 \[M^+^\]; Anal. Calcd. for C~15~H~11~Cl~2~NO~2~: C, 58.46; H, 3.60; N, 4.55; Found: C, 58.23; H, 3.92; N, 4.67.

*7-Chloro-2-methyl-2,3-dihydro-1H-benzo\[e\]\[1,4\]oxazepin-5-one* (**3h**): Yellowish oil. ^1^H-NMR (400 MHz, CDCl~3~): 7.64 (m, 1H), 7.45 (br, 1H), 7.06--7.23 (m, 2H), 4.6 (dd, *J* = 12.2, 8.1 Hz, 1H), 3.98 (dd, *J* = 12.2, 5.6 Hz, 1H), 3.12--3.71 (m, 1H), 1.36 (d, *J* = 7.2 Hz, 3H); ^13^C-NMR (100 MHz, CDCl~3~): 168.5, 147.3, 133.1, 130.2, 123.1, 116.8, 109.3, 77.5, 53.4, 18.3; EIMS (*m*/*z*): 211 \[M^+^\]; Anal. Calcd. for C~10~H~10~ClNO~2~: C, 56.75; H, 4.76; N, 6.62; Found: C, 56.89; H, 5.18; N, 6.34.

*7-Methyl-2-phenyl-2,3-dihydro-1H-benzo\[e\]\[1,4\]oxazepin-5-one* (**3i**): Yellowish oil. ^1^H-NMR (400 MHz, CDCl~3~): 7.58 (m, 1H), 7.41 (br, 1H), 7.06--7.40 (m, 7H), 5.00 (dd, *J* = 8.0, 5.6 Hz, 1H), 4.06 (dd, *J* = 12.2, 8.0 Hz, 1H), 3.92 (dd, *J* = 12.2, 5.6 Hz, 1H), 2.40 (s, 3H). ^13^C-NMR (100 MHz, CDCl~3~): 168.5, 147.2, 139.4, 133.3, 130.8, 128.9, 127.7, 126.9, 126.2, 116.7, 109.3, 77.8, 60.3, 25.3; EIMS (*m*/*z*): 253 \[M^+^\]; Anal. Calcd. for C~16~H~15~NO~2~: C, 75.87; H, 5.97; N, 5.53; Found: C, 75.65; H, 6.28; N, 5.33.

*7-Methyl-2-p-tolyl-2,3-dihydro-1H-benzo\[e\]\[1,4\]oxazepin-5-one* (**3j**): Yellowish oil. ^1^H-NMR (400 MHz, CDCl~3~): 7.56 (m, 1H), 7.44 (br, 1H), 7.06--7.36 (m, 6H), 4.98 (dd, *J* = 7.9, 5.6 Hz, 1H), 4.02 (dd, *J* = 12.2, 7.9 Hz, 1H), 3.90 (dd, *J* = 12.2, 5.6 Hz, 1H), 2.39 (s, 6H); ^13^C-NMR (100 MHz, CDCl~3~): 168.2, 147.5, 138.3, 135.1, 132.4, 130.8, 128.8, 127.5, 126.2, 116.2, 109.1, 77.2, 60.5, 25.8, 25.3; EIMS (*m*/*z*): 267 \[M^+^\]; Anal. Calcd. for C~17~H~17~NO~2~: C, 76.38; H, 6.41; N, 5.24; Found: C, 76.69; H, 6.24; N, 5.53.

*2-(4-Chloro-phenyl)-7-methyl-2,3-dihydro-1H-benzo\[e\]\[1,4\]oxazepin-5-one* (**3k**): Yellowish oil. ^1^H-NMR (400 MHz, CDCl~3~): 7.60 (m, 1H), 7.47 (br, 1H), 7.06-7.44 (m, 6H), 5.08 (dd, *J* = 8.0, 5.7 Hz, 1H), 4.10 (dd, *J* = 12.2, 8.0 Hz, 1H), 3.98 (dd, *J* = 12.2, 5.7 Hz, 1H), 2.42 (s, 3H); ^13^C-NMR (100 MHz, CDCl~3~): 168.1, 147.5, 139.6, 133.5, 132.2, 131.1, 128.3, 127.5, 126.4, 115.7, 109.7, 77.4, 60.7, 25.4; EIMS (*m*/*z*): 287 \[M^+^\]; Anal. Calcd. for C~16~H~14~ClNO~2~: C, 66.79; H, 4.90; N, 4.87; Found: C, 67.09; H, 4.99; N, 4.54.

*2,7-Dimethyl-2,3-dihydro-1H-benzo\[e\]\[1,4\] xazepine-5-one* (**3l**): Yellowish oil. ^1^H-NMR (400 MHz, CDCl~3~): 7.62 (m, 1H), 7.43 (br, 1H), 7.04--7.20 (m, 2H), 4.56 (dd, *J* = 12.2, 8.0 Hz, 1H), 3.93 (dd, *J* = 12.2, 5.4 Hz, 1H), 3.10--3.70 (m, 1H), 2.41 (s, 3H), 1.34 (d, *J* = 7.0 Hz, 3H); ^13^C-NMR (100 MHz, CDCl~3~): 168.3, 147.1, 133.5, 130.9, 126.8, 115.8, 109.2, 77.5, 53.4, 25.3, 18.3; EIMS (*m*/*z*): 191 \[M^+^\]; Anal. Calcd. for C~11~H~13~NO~2~: C, 69.09; H, 6.85; N, 7.32; Found: C, 69.41; H, 6.55; N, 7.16.

*5a,6,7,8,9,9a-Hexahydro-5H-10-oxa-5-aza-dibenzo\[a,d\]cyclohepten-11-one* (**5a**): Yellowish oil. ^1^H-NMR (400 MHz, CDCl~3~): 7.60 (m, 1H), 7.48 (br, 1H), 7.02--7.39 (m, 3H), 4.22 (dd, *J* = 11.3, 3.4 Hz, 1H), 3.11 (dd, *J* = 11.3, 3.5 Hz, 1H), 1.61--1.93 (m, 4H), 1.43--1.52 (m, 4H); ^13^C-NMR (100 MHz, CDCl~3~): 168.2, 147.6, 132.6, 130.1, 118.2, 115.9, 108.8, 85.8, 56.1, 28.5, 27.6, 22.9, 21.7; EIMS (*m*/*z*): 217 \[M^+^\]; Anal. Calcd. for C~13~H~15~NO~2~: C, 71.87; H, 6.96; N, 6.45; Found: C, 71.72; H, 6.66; N, 6.73.

*2-Chloro-5a,6,7,8,9,9a-hexahydro-5H-10-oxa-5-aza-dibenzo\[a,d\]cyclohepten-11-one* (**5b**): Yellowish oil. ^1^H-NMR (400 MHz, CDCl~3~): 7.62 (m, 1H), 7.49 (br, 1H), 7.05--7.43 (m, 2H), 4.26 (dd, *J* = 11.3, 3.5 Hz, 1H), 3.11 (dd, *J* = 11.3, 3.7 Hz, 1H), 1.62--1.95 (m, 4H), 1.43--1.54 (m, 4H); ^13^C-NMR (100 MHz, CDCl~3~): 168.3, 147.1, 133.1, 130.4, 122.5, 116.1, 108.2, 85.6, 56.5, 28.8, 27.2, 22.7, 21.5; EIMS (*m*/*z*): 251 \[M^+^\]; Anal. Calcd. for C~13~H~14~ClNO~2~: C, 62.03; H, 5.61; N, 5.56; Found: C, 62.19; H, 5.31; N, 5.34.

*2-Methyl-5a,6,7,8,9,9a-hexahydro-5H-10-oxa-5-aza-dibenzo\[a,d\]cyclohepten-11-one* (**5c**): Yellowish oil. ^1^H-NMR (400 MHz, CDCl~3~): 7.58 (m, 1H), 7.46 (1H, br), 7.00--7.35 (m, 2H), 4.20 (dd, *J* = 11.2, 3.2 Hz, 1H), 3.09 (dd, *J* = 11.2, 3.4 Hz, 1H), 2.40 (s, 3H), 1.60--1.91 (m, 4H), 1.42--1.50 (m, 4H); ^13^C-NMR (100 MHz, CDCl~3~): 168.4, 147.3, 133.4, 130.8, 126.1, 116.1, 108.5, 85.4, 56.3, 28.7, 27.8, 22.8, 21.5; EIMS (*m*/*z*): 231 \[M^+^\]; Anal. Calcd. for C~14~H~17~NO~2~: C, 72.70; H, 7.41; N, 6.06; Found: C, 72.99; H, 7.28; N, 6.48.

3. Experimental Section {#sec3-molecules-22-00053}
=======================

3.1. General Procedure for Preparation of ***L1***--***L6*** {#sec3dot1-molecules-22-00053}
------------------------------------------------------------

Dimethylformamide dimethyl acetal (DMF-DMA) (10 mmol, 1.19 g) and 1-(1-hydroxy-1*H*-inden-2-yl)-ethanone (10 mmol, 1.74 g) were dissolved in *p*-xylene (5 mL). Additionally, the mixture was refluxed during a period of 5--12 h, during which time a yellow precipitate formed. The precipitate was filtered out and washed with petroleum ether three times. The solid was vacuum-dried, and 1.89 g (yield 94%) of a yellow solid were obtained, **L1** 2-(2-dimethylamino-vinyl)-1*H*-inden-1-ol. ^1^H-NMR (400 MHz, CDCl~3~): δ 7.23 (m, 2H), 7.17--7.07 (t, *J* = 8.0 Hz, 2H), 7.01--6.90 (t, *J* = 7.8 Hz, 1H), 6.60 (s, 1H), 6.07--6.05 (d, *J* = 12 Hz, 1H), 2.47 (s, 3H), 2.42 (s, 3H); ^13^C-NMR (100 MHz, CDCl~3~): δ 146.1, 141.2, 133.8, 130.2, 127.9, 126.9, 123.2,121.2, 120.6, 104.1, 75.4, 46.1, 38.6.

3.2. 2-Phenyl-2,3-dihydro-1H-benzo\[e\]\[1,4\]oxazepin-5-one *(**3a**)* {#sec3dot2-molecules-22-00053}
-----------------------------------------------------------------------

A mixture of phenylamine **1a** (0.5 mmol, 46.5 mg), (1-chloro-vinyl)-benzene **2a** (0.6 mmol, 83.4 mg), CuI (10 mol %, 9.5 mg), **L1** (10 mol %, 20.1 mg) and Cs~2~CO~3~ (2 equiv., 325.8 mg) in DMSO (4 mL) was stirred in CO~2~ at 100 °C for 10 h. After completion of the reaction, the mixture was quenched with saturated salt water (10 mL); the solution was extracted with ethyl acetate (3 × 10 mL). The organic layers were combined and dried over sodium sulfate. The pure product was obtained by flash column chromatography on silica gel to afford **3a** 96.8 mg in 81% yield. The spectroscopic data of all of the products are represented below. Yellowish oil. ^1^H-NMR (400 MHz, CDCl~3~): 7.63 (m, 1H), 7.43 (br, 1H), 7.08--7.43 (m, 8H), 5.07 (dd, *J* = 8.0, 5.7 Hz, 1H), 4.08 (dd, *J* = 12.3, 8.0 Hz, 1H), 3.96 (dd, *J* = 12.3, 5.6 Hz, 1H); ^13^C-NMR (100 MHz, CDCl~3~): 168.3, 147.7, 139.1, 132.9, 130.3, 128.6, 127.5, 126.6, 117.8, 116.4, 109.1, 77.6, 60.2; EIMS (*m*/*z*): 239 \[M^+^\]; Anal. Calcd. for C~15~H~13~NO~2~: C, 75.30; H, 5.48; N, 5.85; Found: C, 75.62; H, 5.13; N, 5.68.

4. Conclusions {#sec4-molecules-22-00053}
==============

In conclusion, we have found a green protocol for the synthesis of benzo-1,4-oxazepine derivatives involving tandem transformation of C-N coupling/C-H carbonylation. The method was economically viable and relevant to green chemistry.
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Schemes and Tables
==================

![The important benzo-1,4-oxazepine derivatives.](molecules-22-00053-sch001){#molecules-22-00053-sch001}

![A plausible mechanism of the catalytic cycle.](molecules-22-00053-sch002){#molecules-22-00053-sch002}

molecules-22-00053-t001_Table 1

###### 

Optimization of the reaction conditions ^a^.

![](molecules-22-00053-i001)

  Entry   Ligand   Cu Salt      Base         Yield (%) ^b^
  ------- -------- ------------ ------------ ---------------
  1       **L1**   Cu(OAc)~2~   Cs~2~CO~3~   8
  2       **L1**   CuSO~4~      Cs~2~CO~3~   0
  3       **L1**   CuBr         Cs~2~CO~3~   23
  4       **L1**   CuBr~2~      Cs~2~CO~3~   19
  5       **L1**   CuI          Cs~2~CO~3~   81
  6       **L2**   CuI          Cs~2~CO~3~   29
  7       **L3**   CuI          Cs~2~CO~3~   36
  8       **L4**   CuI          Cs~2~CO~3~   47
  9       **L5**   CuI          Cs~2~CO~3~   16
  10      **L6**   CuI          Cs~2~CO~3~   38
  11      **L1**   CuI          K~2~CO~3~    42
  12      **L1**   CuI          K~3~PO~4~    0
  13      **L1**   CuI          Cs~2~CO~3~   61 ^c^
  14      **L1**   CuI          Cs~2~CO~3~   69 ^d^
                                             

^a^ Unless otherwise noted, reactions conditions were **1a** (0.5 mmol), **2a** (0.6 mmol), Cu salt (10 mol %), ligand (10 mol %), base (2 eq.), DMSO (4 mL) reacted in CO~2~ at 100 °C for 12 h; ^b^ isolated yield; ^c^ reaction under 90 °C; ^d^ reaction under 110 °C.

molecules-22-00053-t002_Table 2

###### 

Synthesis of benzo-1,4-oxazepin-5-one **3** ^a^.

![](molecules-22-00053-i003)

  Entry   R^1^      R^2^              Product 3   Yield (%) ^b^
  ------- --------- ----------------- ----------- ---------------
  1       H         Ph                            81
  2       H         4-CH~3~C~6~H~4~               78
  3       H         4-ClC~6~H~4~                  85
  4       H         CH~3~                         74
  5       4-Cl      Ph                            79
  6       4-Cl      4-CH~3~C~6~H~4~               76
  7       4-Cl      4-ClC~6~H~4~                  86
  8       4-Cl      CH~3~                         84
  9       4-CH~3~   Ph                            76
  10      4-CH~3~   4-CH~3~C~6~H~4~               75
  11      4-CH~3~   4-ClC~6~H~4~                  82
  12      4-CH~3~   CH~3~                         72

^a^ Reactions conditions were **1** (0.5 mmol), **2** (0.6 mmol), CuI (10 mol %), **L1** (10 mol %), Cs~2~CO~3~ (2 equiv.), DMSO (4 mL) at 100 °C reacted in CO~2~ for 10 h; ^b^ isolated yield.

molecules-22-00053-t003_Table 3

###### 

Synthesis of benzo-1,4-oxazepin-5-one **5** ^a^.

![](molecules-22-00053-i016)

  Entry   R^1^      Product 5   Yield (%) ^b^
  ------- --------- ----------- ---------------
  1       H                     78
  2       4-Cl                  84
  3       4-CH~3~               75

^a^ Reactions conditions were **1** (0.5 mmol), **2** (0.6 mmol), CuI (10 mol %), **L1** (10 mol %), Cs~2~CO~3~ (2 equiv.), DMSO (4 mL) at 100 °C reacted in CO~2~ for 10 h; ^b^ isolated yield.
